Compare Nebius Group NV (NBIS) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Tenet Healthcare Corporation — how do they compare? Nebius Group NV trades at $225.8 (market cap $64.47B), while Tenet Healthcare Corporation trades at $260 (market cap $20.98B). The key difference: Nebius Group NV is far larger — about 3.1× Tenet Healthcare Corporation's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nebius Group NV for 24 Days and Tenet Healthcare Corporation for 15 Days on average.
| NBIS | THC | |
|---|---|---|
Market Cap | $64.47B | $20.98B |
Volume | 17,733,531 | 428,008 |
Sector | Technology | Health |
52-Week High | $286.69 | $280.77 |
52-Week Low | $73.87 | $161.37 |
Typical Hold Time | 24 Days | 15 Days |
Enterprise Value | $66.60B | $32.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $237.07, down 5.08% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company shows strong revenue growth with $529.8M in 2025 revenue and a $37B backlog, though profitability remains challenged with a net margin of 3.13%. Recent news highlights significant AI infrastructure deals with Meta, Nvidia, and Palantir, while analyst consensus remains strongly bullish with 82% buy ratings.
The outlook for NBIS is growth-focused but carries execution risks. The stock offers substantial upside to the $272.70 consensus target, supported by AI infrastructure demand and strategic partnerships. Key risks include high valuation multiples (P/E 912), negative cash flow from investing activities, and insider selling. Investors should weigh the company's rapid expansion against its current profitability challenges and competitive pressures in the AI cloud sector.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 82.83% gross margins, and 53.31% ROE. Recent news highlights strong cash flow supporting capital returns, with Q3 2026 results expected October 29, 2026.
THC presents compelling value with a 10.04 P/E ratio and 81.25% analyst buy ratings. Upside potential to $283.36 consensus target exists, though negative cash flow trends and insider selling warrant monitoring. The stock's premium valuation (P/B 4.49) requires sustained execution amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
